• ABOUT
    • WHY NOTICIAS NEWSWIRE?
    • GUARANTEED VISIBILITY NETWORK
    • OUR TEAM
    • TESTIMONIALS
    • TERMS
  • PRICING
  • ORDER FORM
  • FOR JOURNALISTS
  • RESOURCES
    • HISPANIC MARKET INSIGHTS AND ARTICLES
    • CELEBRATE HISPANIC GREATNESS
    • CELEBRATE HISPANIC GREATNESS – QUIZ
    • SEO TIPS
    • NOTICIAS NEWSWIRE FEEDS PLUGIN
    • NOTICIAS NEWSWIRE WIDGET GENERATOR
    • Hispanic PR Blog – Weekly Newsletter
  • CONTACT
  • REQUEST INFO
  • English
    • Español

Noticias Newswire - Hispanic Press Release Distribution Wire Service

The world changed. Your wire should 'tu'

Noticias Newswire - Hispanic Press Release Distribution Wire Service
NEW! EDITORIAL FEATURES ARTS & CULTURE AUTOMOTIVE BUSINESS & FINANCE EDUCATION ENTERTAINMENT FAMILY & LIVING FASHION & BEAUTY FOOD & BEVERAGE GENERAL NEWS HEALTH HUMAN INTEREST IMMIGRATION INTERNET & TECHNOLOGY MARKETING/ SOCIAL MEDIA PUBLIC AFFAIRS/GOVERNMENT SPORTS & RECREATION TRAVEL & TOURISM
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™

— Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) —

February 13, 2024 | 09:27 am
  • Español

TORONTO, CA — February 13, 2024 — (NOTICIAS NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the Company’s first indication-specific drug registration for Trunerox™ issued by INVIMA, the Health Authority of Colombia.

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs. It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.

The Trunerox drug approval (Registro Sanitario como medicamento) was issued by INVIMA, after a detailed process of verification of all legal, technical, and pharmacological requirements were fulfilled in accordance with Decree 677 of 1995 and other applicable regulations. The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS). Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.

Trunerox is Avicanna’s proprietary oral formulation with 10% cannabidiol (CBD) and is manufactured with good manufacturing practices GMP at Altea Farmacéutica in Bogota, Colombia utilizing CBD manufactured at the Avicanna’s majority-owned subsidiary Santa Marta Golden Hemp SAS.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:

• Medical Cannabis & Wellness Products (RHO Phyto™): The formulary offers a diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids and is supported with ongoing patient, and medical community education. RHO Phyto has been established as a leading medical brand in Canada and is currently available nationwide to patients across several medical channels and continues to expand into new international markets.

• Pharmaceutical Preparations and Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed an extensive pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America.

About MyMedi.ca
MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc and features a diverse portfolio of products and a pharmacist led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborating with public and private providers for adjudication and reimbursement and educational resources to facilitate the incorporation of medical cannabis into health care regimens. 

The Company posts updates through videos from the Company YouTube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2023 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Source Avicanna Inc.

For more information about Avicanna, visit our website, follow us on social media LinkedIn, Twitter, Facebook, or Instagram.

CONTACT

Ivana Maric
info@avicanna.com

CONNECT WITH US

FacebookXLinkedInInstagram

MEDIA ASSETS

WEBSITE

https://www.avicanna.com/

CONNECT WITH US

Noticias Newswire


Tweets by Noticias Newswire

PR Pros: Unleash your Hispanic PR excellence with our Trade Journal + Weekly Newsletter!

Click here to subscribe!

Click here to subscribe and receive the latest industry news, professional development tips, webinars, and more!

OUR PARTNERS 

  PRODUPRODU
  LATINA MEETUPLATINA MEETUP
  MIRA CLICKMIRA CLICK
  HISPANIC YAHISPANIC YA
  LISTAS LOCALESLISTAS LOCALES
  THE AMIGOS CLUBTHE AMIGOS CLUB
  Buena Vida MediaBuena Vida Media
  Talento UnlimitedTalento Unlimited
  Hispanic MediaHispanic Media
el Sol Latinoel Sol Latino
Latin Life DenverLatin Life Denver
Mónica TaherBMónica Taher
La Numero 1La Numero 1
Hispanic PR BlogHispanic PR Blog
DLA ClasificadosDLA Clasificados
  Estilos BlogEstilos Blog
  Brilla MediaBrilla Media
  Hispanic Market AdvisorsHispanic Market Advisors
  Espresso con LecheEspresso con Leche
  Ejecutiva MagazineEjecutiva Magazine
  C|net en Español C|net en Español
  CandypoloozaCandypolooza
  Be LatinaBe Latina
Altisimo LiveAltísimo Live
MA Latino NewsMA Latino News
Latino BaseballLatino Baseball
Latino BoxingLatino Boxing
Latino SEMLLatino SEM
Estilos BlogEstilos Blog
Estilos MediaEstilos Media
Sofrito For Your SoulSofrito For Your Soul
Latin Heat MediaLatin Heat Media
Latinas in BusinessLatinas in Business
Super Latina TVSuper Latina TV
Political CortaditoPolitical Cortadito
PapiBloggerPapiBlogger
CT Latino NewsCT Latino News
Diario Las AmericasDiario Las Americas
El Mundo BostonEl Mundo Boston
Celebrando Latinas MagazineCelebrando Latinas Magazine
El Latino Newspaper – San DiegoEl Latino Newspaper – San Diego
105.3 LA Zeta105.3 LA Zeta
NH Latino NewsNH Latino News
Negocios MagazineNegocios Magazines
QueMeansWhatQueMeansWhat
TamaccTamacc
Los Tweens and TeensLos Tweens and Teens
Latino Business ReportLatino Business Report
Hispanic HoustonHispanic Houston
Juan of WordsJuan of Words
Latin Vibes RadioLatin Vibes Radio
Hip-Hop MundoHip-Hop Mundo
Latinas Life StyleLatinas Life Style
Downtown Miami and Brickell Chamber of Commerce™Downtown Miami and Brickell Chamber of Commerce
  • NEW! EDITORIAL FEATURES
  • ARTS & CULTURE
  • AUTOMOTIVE
  • BUSINESS & FINANCE
  • EDUCATION
  • ENTERTAINMENT
  • ENVIRONMENT & SUSTAINABILITY
  • FAMILY & LIVING
  • FASHION & BEAUTY
  • FOOD & BEVERAGE
  • GENERAL NEWS
  • HEALTH
  • HUMAN INTEREST
  • IMMIGRATION
  • INTERNET & TECHNOLOGY
  • MARKETING/ SOCIAL MEDIA
  • PUBLIC AFFAIRS/GOVERNMENT
  • SPIRITUALITY
  • SPORTS & RECREATION
  • TRAVEL & TOURISM

© 2025 Noticias Newswire
Hispanic Press Release Distribution Wire Service. All rights reserved.

Hispanic Market